A one-minute look at managed care news during the week of March 16, 2015, including bills from Congress to fix the sustainable growth rate formula and anticipation over the PCSK9 inhibitors.
After enacting 17 temporay fixes, Congress has finally introduced legislation to fix the sustainable growth rate formula. A vote is anticipated next week ahead of an April 1 deadline, after which doctors would face a 21.2% cut in payments.
Data presented at the American College of Cardiology's Annual Scientific Sessions showed that the highly anticipated cholesterol-fighting PCSK9 inhibitor, evolocumab, also cuts cardiovascular events by half.
Finally, Patient-Centered Diabetes Care, hosted by The American Journal of Managed Care and Joslin Diabetes Center, is almost here. Don't forget to check out the agenda and register: http://www.ajmc.com/meetings/pcdc15
Trump Administration’s Message to Supreme Court Puts New Wrinkle in Braidwood Case
February 21st 2025The Trump administration argues that HHS Secretary Robert F. Kennedy Jr can overrule the US Preventive Services Task Force to determine the preventive services covered under the Affordable Care Act.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
5 Key Health Care Moments During President Trump's First Month Back in Office
February 21st 2025President Donald J. Trump pushed for significant health care changes during his first month back in office, through executive orders affecting managed care, drug pricing, and clinical trial diversity guidance.
Read More
Same-Day Breast Imaging Gaps Reveal Health Care Disparities
February 18th 2025For this retrospective study, the authors examined data on more than 3 million screening mammographies for more than 1 million female patients; of the screenings, 23.6% had abnormal results and only 6.7% were recommended for biopsy.
Read More